Orally Disintegrating Mini-Tablets: Formulation Strategies, Evaluation Methods, And Applications in Pediatric and Geriatric Drug Delivery

Oral drug delivery systems continue to be the most widely utilized route for drug administration due to their simplicity, patient convenience, non-invasive nature, and cost-effectiveness. Conventional dosage forms such as tablets and capsules are preferred because they provide accurate dosing, good stability, and ease of large-scale manufacturing. These systems are designed to release the drug in the gastrointestinal tract, allowing systemic absorption and therapeutic action. Despite these advantages, traditional oral dosage forms are not always suitable for all patient populations, particularly pediatric and geriatric groups, who often face challenges with standard formulations [1].

Pediatric and geriatric patients require special consideration due to physiological and functional differences. Dysphagia, or difficulty in swallowing, is a major limitation associated with conventional tablets. In children, especially infants and toddlers, the swallowing reflex is not fully developed, making it difficult to administer solid dosage forms. Similarly, elderly patients often experience age-related conditions such as reduced saliva secretion, neurological disorders, and muscular weakness, which impair their ability to swallow tablets or capsules effectively. These issues frequently lead to poor compliance, incomplete dosing, or unsafe practices such as tablet crushing, which may alter drug release profiles and reduce therapeutic efficacy [2]. Moreover, conventional tablets lack dose flexibility, which is critical in pediatrics where dosing is often weight-based. Liquid formulations are commonly used as alternatives; however, they suffer from drawbacks such as instability, inaccurate dosing, unpleasant taste, and the need for preservatives, which can affect patient adherence [3].

To address these limitations, orally disintegrating dosage forms (ODDs), particularly orally disintegrating tablets (ODTs), have been developed as patient-friendly alternatives. These formulations are designed to disintegrate rapidly in the oral cavity without the need for water, typically within seconds. ODTs improve patient compliance by eliminating swallowing difficulties and offering convenience during administration. In some cases, they may also enhance the onset of action due to partial pre-gastric absorption. Additionally, ODTs combine the advantages of both solid and liquid dosage forms, providing stability during storage and ease of administration at the time of use [4]. The incorporation of taste-masking technologies further enhances their acceptability, especially in pediatric patients where palatability is a key determinant of adherence [5].

However, ODTs are not without limitations. Many conventional ODTs are relatively large and fragile, making them difficult to handle, transport, and package. Their mechanical strength is often compromised due to the need for rapid disintegration, which can lead to breakage during handling. Furthermore, dose flexibility remains limited, particularly when precise dose adjustments are required. These challenges have led to the development of mini-tablet technology as an innovative solution to improve oral drug delivery [6].

Mini-tablets are small-sized tablets, typically ranging from 1 to 3 mm in diameter, designed to be administered either as single units or multiple units to achieve the required dose. Their small size enhances swallowability and reduces the risk of choking, making them particularly suitable for pediatric and geriatric populations. Research has demonstrated that even very young children can safely accept and swallow mini-tablets, highlighting their potential as an age-appropriate dosage form. In addition to improved patient acceptability, mini-tablets offer uniform drug distribution, better content uniformity, and the possibility of modified or controlled drug release profiles [7]. The multi-unit nature of mini-tablets also reduces the risk of dose dumping and variability in drug absorption, providing more consistent therapeutic outcomes [8].

The combination of orally disintegrating technology with mini-tablets has resulted in the development of orally disintegrating mini-tablets (ODMTs), which represent a significant advancement in patient-centric drug delivery. ODMTs are designed to disintegrate rapidly in the oral cavity while maintaining the advantages of multi-particulate systems. This hybrid approach addresses many of the limitations associated with conventional ODTs and liquid formulations. ODMTs provide improved mechanical strength, enhanced stability, and greater flexibility in dosing, as multiple mini-tablets can be administered to achieve the desired dose. Their small size also minimizes the risk of choking and improves patient comfort during administration [9].

Compared to liquid formulations, ODMTs offer superior stability and eliminate the need for preservatives, thereby reducing the risk of microbial contamination. They also provide accurate dosing without the variability associated with measuring liquids. In contrast to conventional ODTs, ODMTs are less fragile and more robust, making them easier to handle and package. Additionally, their multi-unit structure allows for better control over drug release and absorption, improving therapeutic efficiency [10].

Overall, orally disintegrating mini-tablets represent a promising and innovative approach to oral drug delivery. By combining the advantages of mini-tablets and orally disintegrating systems, ODMTs address the key challenges associated with conventional dosage forms and offer a patient-friendly alternative for pediatric and geriatric populations. Continued advancements in formulation technologies and manufacturing processes are expected to further enhance their potential, making ODMTs an important focus in the development of future pharmaceutical dosage forms.

2. Pediatric and Geriatric Drug Delivery Challenges

2.1 Pediatric Drug Delivery Issues

Drug delivery in pediatric populations presents distinct and multifaceted challenges due to physiological, developmental, and behavioral differences compared to adults. These challenges necessitate the design of age-appropriate formulations that ensure safety, efficacy, and patient acceptability. Among the most critical issues in pediatric drug delivery are swallowing difficulties, the need for dose flexibility, taste masking requirements, and safety considerations.

Swallowing difficulties are one of the most significant barriers in pediatric drug administration. Infants and young children often lack fully developed swallowing reflexes, making it difficult for them to ingest conventional solid dosage forms such as tablets and capsules. This limitation frequently leads to resistance, incomplete dosing, or refusal of medication. Even in older children, fear of choking and discomfort during swallowing can negatively impact adherence to prescribed therapies. As a result, caregivers often resort to modifying adult dosage forms by crushing tablets or mixing them with food or liquids. However, such practices can alter the pharmacokinetic properties of drugs, potentially affecting their bioavailability and therapeutic outcomes [11]. Additionally, improper administration techniques may increase the risk of aspiration, particularly in infants and toddlers.

Another major challenge in pediatric drug delivery is dose flexibility. Unlike adults, pediatric patients require individualized dosing based on factors such as age, body weight, and developmental stage. Standard fixed-dose formulations are often unsuitable, as they do not allow precise dose adjustments. This creates a reliance on liquid formulations, which can be measured and adjusted more easily. However, liquid dosage forms are associated with issues such as dosing inaccuracies due to measurement errors, instability, and the need for specialized storage conditions. The lack of flexible solid dosage forms further complicates pediatric pharmacotherapy, highlighting the need for innovative systems that can deliver accurate and adjustable doses [12]. Multiparticulate systems, such as mini-tablets, have emerged as promising alternatives, offering the possibility of dose titration through the administration of multiple units.

Taste masking is another critical factor influencing pediatric drug delivery. Children are highly sensitive to taste, particularly bitterness, which is a common characteristic of many active pharmaceutical ingredients. Unpleasant taste is a major cause of poor compliance and treatment failure in pediatric patients. As a result, effective taste-masking strategies are essential in the development of pediatric formulations. Various approaches, including the use of sweeteners, flavoring agents, polymer coatings, and complexation techniques, are employed to improve palatability. However, achieving optimal taste masking without compromising drug release and bioavailability remains a significant challenge. In some cases, excessive use of sweeteners or flavors may raise additional concerns related to dental health or metabolic effects, particularly with long-term use [13]. Therefore, formulation scientists must carefully balance palatability with safety and therapeutic performance.

Safety concerns are paramount in pediatric drug delivery and encompass a wide range of factors, including excipient safety, dosing accuracy, and the risk of adverse effects. Children are not simply “small adults”; their metabolic pathways, organ functions, and enzymatic systems are still developing, which can influence drug absorption, distribution, metabolism, and excretion. This makes them more vulnerable to dosing errors and adverse drug reactions. Excipients commonly used in adult formulations, such as preservatives, colorants, and solvents, may not be safe for pediatric use. For example, certain preservatives have been associated with toxicity in neonates, emphasizing the need for careful selection of formulation components [14].

Moreover, the risk of medication errors is higher in pediatric populations due to the need for dose calculations and adjustments. Inaccurate dosing can lead to under-treatment or toxicity, both of which can have serious consequences. Caregiver involvement in drug administration further introduces variability, as errors in measurement or administration techniques are common. Additionally, the acceptability of dosage forms plays a crucial role in ensuring adherence and safety. A formulation that is difficult to administer or unpalatable may result in missed doses or incomplete therapy, ultimately affecting clinical outcomes [15].

In recent years, regulatory agencies have emphasized the importance of developing pediatric-friendly formulations that address these challenges. Guidelines now encourage the use of age-appropriate dosage forms, safe excipients, and robust clinical evaluation in pediatric populations. Advances in pharmaceutical technology, including orally disintegrating systems and multiparticulate dosage forms, have shown promise in overcoming many of the limitations associated with traditional formulations. These approaches aim to improve swallowability, enable dose flexibility, enhance palatability, and ensure safety, thereby optimizing therapeutic outcomes in pediatric patients [15].

In conclusion, pediatric drug delivery is associated with several critical challenges that require careful consideration during formulation development. Swallowing difficulties, the need for flexible dosing, taste masking requirements, and safety concerns collectively influence the design and performance of pediatric dosage forms. Addressing these issues through innovative and patient-centric approaches is essential for improving medication adherence, safety, and therapeutic efficacy in this vulnerable population.

2.2 Geriatric Drug Delivery Challenges

Geriatric patients represent a rapidly growing population with unique healthcare needs, particularly in the context of drug delivery. Age-related physiological changes, comorbidities, and functional limitations significantly influence the safety, efficacy, and acceptability of pharmaceutical dosage forms. Among the most prominent challenges in geriatric drug delivery are dysphagia, polypharmacy, cognitive impairment, and reduced saliva production.

Dysphagia, or difficulty in swallowing, is highly prevalent among elderly individuals and is considered one of the primary barriers to effective oral drug administration. It is often associated with neurological disorders such as stroke, Parkinson’s disease, and age-related muscular degeneration. Dysphagia can lead to discomfort, choking, or aspiration, thereby increasing the risk of non-compliance and treatment failure. Many geriatric patients struggle with swallowing conventional tablets and capsules, prompting them or their caregivers to crush or split medications. However, such modifications can alter drug release characteristics, compromise dosage accuracy, and potentially lead to adverse effects [16]. Consequently, the need for alternative dosage forms that are easy to administer without compromising therapeutic efficacy is critical in this population.

Polypharmacy, defined as the concurrent use of multiple medications, is another major concern in geriatric care. Elderly patients often suffer from multiple chronic conditions such as hypertension, diabetes, and cardiovascular disorders, necessitating the use of several drugs simultaneously. This increases the complexity of medication regimens and the risk of drug–drug interactions, adverse drug reactions, and medication errors. Polypharmacy can also lead to reduced adherence, as patients may find it difficult to manage multiple medications with different dosing schedules. Furthermore, the cumulative burden of taking several large tablets or capsules can exacerbate swallowing difficulties and negatively impact patient compliance [17].

Cognitive impairment is a significant challenge that further complicates drug administration in geriatric patients. Conditions such as dementia and Alzheimer’s disease can impair memory, understanding, and the ability to follow medication instructions. Patients with cognitive decline may forget to take their medications, take incorrect doses, or fail to adhere to prescribed regimens. This not only reduces therapeutic effectiveness but also increases the risk of adverse outcomes. Caregiver involvement is often required in such cases, but this introduces additional variability and potential for administration errors. Therefore, dosage forms that are simple to administer and require minimal patient intervention are essential to ensure safe and effective therapy in cognitively impaired individuals [18].

Reduced saliva production, or xerostomia, is another common issue in elderly patients, often resulting from age-related changes or as a side effect of medications. Saliva plays a crucial role in the disintegration and swallowing of oral dosage forms. A decrease in saliva production can make it difficult to swallow tablets and capsules, leading to discomfort and an increased risk of esophageal irritation. Additionally, inadequate saliva can delay the disintegration of certain dosage forms, affecting drug release and absorption. This condition further highlights the need for formulations that can disintegrate rapidly in the oral cavity without relying heavily on saliva [19].

2.3 Need for Patient-Centric Dosage Forms

The challenges associated with pediatric and geriatric drug delivery have underscored the importance of developing patient-centric dosage forms that prioritize usability, safety, and therapeutic effectiveness. Patient-centric formulations are designed to accommodate the specific needs and limitations of target populations, thereby improving compliance and clinical outcomes.

One of the primary objectives of patient-centric dosage forms is to enhance medication compliance. Non-compliance is a significant issue in both pediatric and geriatric populations and is often linked to factors such as difficulty in swallowing, complex dosing regimens, and poor palatability. In geriatric patients, physical and cognitive limitations further contribute to non-adherence. Patient-friendly formulations, such as orally disintegrating systems and mini-tablets, can simplify drug administration by eliminating the need for water and reducing the effort required to swallow. Improved acceptability of dosage forms directly translates into better adherence to treatment regimens and more consistent therapeutic outcomes [20].

Accurate dosing is another critical aspect of patient-centric drug delivery. In pediatric patients, dosing often needs to be adjusted based on body weight or age, while in geriatric patients, dose modifications may be required due to altered pharmacokinetics and organ function. Conventional dosage forms do not always allow for precise dose adjustments, increasing the risk of underdosing or overdosing. Patient-centric approaches, such as multiparticulate systems, enable flexible dosing by allowing the administration of multiple units to achieve the desired dose. This approach not only improves dose accuracy but also reduces variability in drug exposure, thereby enhancing safety and efficacy [21].

In addition to compliance and dosing accuracy, patient-centric dosage forms aim to improve the overall patient experience. Factors such as ease of handling, palatability, and convenience play a crucial role in determining the success of a formulation. For example, dosage forms that disintegrate quickly in the mouth can reduce discomfort and anxiety associated with swallowing, particularly in elderly patients with dysphagia. Similarly, formulations with effective taste masking can improve acceptance in both children and older adults. By addressing these factors, patient-centric drug delivery systems contribute to better health outcomes and improved quality of life [22].

Regulatory authorities and healthcare organizations have increasingly recognized the importance of patient-centric drug development. Guidelines now emphasize the need for age-appropriate formulations that consider the specific requirements of different patient populations. Advances in pharmaceutical technologies, including the development of orally disintegrating mini-tablets, have made it possible to design dosage forms that meet these criteria. These innovations offer a promising approach to overcoming the limitations of traditional formulations and ensuring that medications are both effective and acceptable to patients [23][24].

In conclusion, geriatric drug delivery is associated with several challenges, including dysphagia, polypharmacy, cognitive impairment, and reduced saliva production, all of which can significantly impact medication adherence and therapeutic outcomes. The development of patient-centric dosage forms that enhance compliance and ensure accurate dosing is essential to address these challenges. Such approaches represent a critical step toward optimizing drug therapy and improving the quality of healthcare for vulnerable populations.

3. Orally Disintegrating Mini-Tablets (ODMTs)

3.1 Definition and Concept

Orally disintegrating mini-tablets (ODMTs) are an advanced oral solid dosage form that combines the advantages of orally disintegrating tablets with multiparticulate drug delivery systems. These dosage forms are typically characterized by a small size, generally ranging from 2 to 4 mm in diameter, and are designed to disintegrate rapidly in the oral cavity without the need for water. Their reduced dimensions significantly enhance patient acceptability, particularly among pediatric and geriatric populations, where swallowing conventional tablets is often problematic [26].

The concept of ODMTs is based on a rapid disintegration mechanism facilitated by the incorporation of superdisintegrants such as crospovidone, croscarmellose sodium, and sodium starch glycolate. These agents promote rapid water uptake and swelling, leading to the quick breakdown of the tablet matrix upon contact with saliva. The high surface area-to-volume ratio of mini-tablets further accelerates the disintegration and dissolution processes. As a result, ODMTs disperse efficiently in the oral cavity, allowing prompt drug release. In certain cases, this rapid disintegration may contribute to a faster onset of action due to partial pre-gastric absorption [27]. Additionally, ODMTs function as multiparticulate systems, consisting of multiple discrete units that distribute uniformly in the gastrointestinal tract, thereby reducing variability in drug absorption.

3.2 Advantages of ODMTs

ODMTs offer several advantages over conventional oral dosage forms, making them particularly suitable for patient-centric drug delivery. One of the most significant benefits is ease of swallowing. Due to their small size, ODMTs are easier to administer and are associated with a reduced risk of choking. Even if complete disintegration does not occur prior to swallowing, their small dimensions facilitate safe ingestion, thereby improving patient compliance [28].

Another important advantage is dose flexibility. ODMTs can be administered as single or multiple units to achieve the desired dose, enabling precise dose adjustment. This is especially beneficial in pediatric populations, where dosing is typically weight-based, and in geriatric patients, where dose modifications may be required due to altered pharmacokinetic profiles. Furthermore, the administration of multiple mini-tablets allows for combination therapies and individualized treatment regimens [29].

ODMTs also demonstrate potential for improved bioavailability. Rapid disintegration in the oral cavity enhances drug dissolution, which may lead to faster absorption. In some instances, partial absorption through the oral mucosa can occur, thereby bypassing first-pass metabolism and increasing systemic drug availability. Moreover, the uniform distribution of multiple units within the gastrointestinal tract reduces variability in drug absorption, resulting in more consistent therapeutic outcomes [30].

Compared to liquid formulations, ODMTs provide superior physicochemical stability. Liquid dosage forms are more susceptible to microbial contamination and chemical degradation and often require the addition of preservatives. In contrast, ODMTs, as solid dosage forms, exhibit enhanced stability, longer shelf life, and reduced dependence on specialized storage conditions. These attributes make them suitable for use in a wide range of healthcare settings [31].

Additionally, ODMTs are highly compatible with multiple unit dosage systems (MUPS). Their multiparticulate nature ensures uniform dispersion throughout the gastrointestinal tract, minimizing the risk of dose dumping and local irritation. This characteristic also enables the development of modified-release formulations by combining mini-tablets with different release profiles, offering greater flexibility in drug delivery design [32].

3.3 Limitations

Despite their advantages, ODMTs present several formulation and manufacturing challenges. One of the primary limitations is manufacturing complexity. The production of mini-tablets requires specialized equipment capable of handling small punches and dies. Achieving uniform compression, adequate mechanical strength, and rapid disintegration simultaneously is technically demanding. Furthermore, scaling up the manufacturing process while maintaining consistent quality increases operational complexity and cost [33].

Content uniformity is another significant concern in ODMT development. Due to the small size of individual units, ensuring uniform distribution of the active pharmaceutical ingredient within each mini-tablet is challenging, particularly for low-dose drugs. Variations in drug content can result in inconsistent dosing, which is particularly critical in pediatric and geriatric populations. Advanced granulation techniques and stringent quality control measures are essential to address this issue [34].

Taste masking also remains a critical challenge in ODMT formulation. Since these dosage forms disintegrate in the oral cavity, the active drug is directly exposed to taste receptors, making palatability a key factor influencing patient compliance. Many drugs possess an inherently bitter taste, necessitating effective taste-masking strategies such as polymer coating, complexation, or the use of sweeteners and flavoring agents. However, achieving efficient taste masking without adversely affecting drug release and bioavailability is difficult. Additionally, the small size of ODMTs limits the extent of coating that can be applied, further complicating formulation design [35].

In summary, ODMTs represent a promising and innovative drug delivery system that addresses many of the limitations associated with conventional oral dosage forms. While they offer significant advantages in terms of patient compliance, dose flexibility, and stability, challenges related to manufacturing, content uniformity, and taste masking must be carefully managed to ensure their successful development and clinical application.

4. Formulation Strategies for Orodispersible Mouth Dissolving Tablets (ODMTs)

4.1 Selection of Active Pharmaceutical Ingredient (API)

The selection of an appropriate active pharmaceutical ingredient (API) is a critical step in the formulation of orodispersible mouth dissolving tablets (ODMTs), as it directly influences the disintegration behavior, patient acceptability, and overall therapeutic efficacy of the dosage form [36–38].

Dose Considerations

ODMTs are generally designed for low-dose drugs, typically below 50 mg, due to limitations in tablet size and the need for rapid disintegration in the oral cavity. High-dose drugs may compromise tablet porosity and delay disintegration, reducing the effectiveness of the formulation [36,37]. Furthermore, higher drug loading can negatively impact mouthfeel and patient compliance.

Solubility and Stability

The solubility of the API plays a significant role in determining the rate of dissolution and onset of action. Drugs with high aqueous solubility are ideal candidates, as they dissolve rapidly in saliva without requiring extensive gastrointestinal processing [38–40].
Stability is another crucial factor, particularly for moisture-sensitive drugs. Since ODMTs often contain hygroscopic excipients, APIs must exhibit chemical and physical stability under humid conditions to maintain shelf life and efficacy.

Taste Characteristics

Because ODMTs disintegrate in the mouth, taste masking becomes essential, especially for bitter or unpleasant-tasting drugs. APIs with inherently acceptable taste profiles are preferred; however, for bitter drugs, advanced taste-masking strategies such as coating, complexation, or use of sweeteners are necessary [41,42].

4.2 Excipients Used in ODMTs

Excipients are fundamental in ensuring rapid disintegration, mechanical strength, and palatability of ODMTs. Their selection and optimization significantly affect the performance of the final product [43].

4.2.1 Superdisintegrants

Superdisintegrants are key components that facilitate rapid tablet breakdown upon contact with saliva.

• Crospovidone:
  Crospovidone is widely used due to its high capillary activity and rapid hydration without gel formation. It promotes fast disintegration by a combination of wicking and swelling mechanisms [44].
• Croscarmellose Sodium:

This cross-linked cellulose derivative exhibits excellent swelling properties, leading to quick tablet disintegration. It is particularly effective at low concentrations and improves tablet porosity [45].

• Sodium Starch Glycolate (SSG):

SSG swells extensively in aqueous environments, enabling rapid tablet breakup. However, excessive use may lead to gelling, which can slow disintegration [46].

4.2.2 Fillers and Diluents

Fillers provide bulk and improve the mechanical strength and mouthfeel of ODMTs.

• Mannitol:
  Mannitol is one of the most commonly used diluents due to its pleasant cooling sensation and sweet taste, which enhances patient acceptability. It also contributes to improved tablet hardness and rapid dissolution [47].
• Lactose:
  Lactose is widely used due to its compressibility and compatibility with various APIs. However, it may not be suitable for lactose-intolerant patients [48].
• Microcrystalline Cellulose (MCC):

MCC offers excellent binding and compressibility properties. It also aids in disintegration by promoting water uptake into the tablet matrix [49].

4.2.3 Binders

Binders are used to impart mechanical strength to ODMTs while maintaining rapid disintegration.

• Polyvinylpyrrolidone (PVP):

PVP is a commonly used synthetic binder that enhances tablet cohesion. It is effective in low concentrations and compatible with a wide range of drugs [50].

• Hydroxypropyl Cellulose (HPC):

HPC serves as both a binder and a film-forming agent. It improves tablet integrity without significantly affecting disintegration time [51].

4.2.4 Lubricants and Glidants

These excipients improve manufacturability by reducing friction and enhancing powder flow.

• Magnesium Stearate:

A widely used lubricant that reduces die-wall friction during compression. However, excessive use may hinder tablet disintegration by forming a hydrophobic layer [52].

• Talc:
  Talc acts as both a lubricant and anti-adherent, preventing sticking during tablet compression [53].
• Colloidal Silicon Dioxide:

This glidant improves powder flow and ensures uniform die filling, which is essential for dose uniformity [54].

4.2.5 Taste Masking Agents

Taste masking is essential for ensuring patient compliance, especially in pediatric and geriatric populations.

• Sweeteners:
  Artificial sweeteners such as aspartame, sucralose, and saccharin are commonly used to mask bitterness and improve palatability [41].
• Flavoring Agents:

Flavors such as mint, citrus, or fruit are incorporated to enhance the sensory experience and mask unpleasant tastes [42].

• Coating Techniques:

Advanced taste-masking approaches involve coating drug particles with polymers to prevent interaction with taste buds. Techniques such as microencapsulation and spray coating are widely employed [55].

5. Drug Release and Bioavailability Considerations in ODMTs

Orodispersible mouth dissolving tablets (ODMTs) are designed to enhance patient compliance while improving drug release characteristics and bioavailability. Their unique mechanism of disintegration in the oral cavity without the need for water allows for rapid drug release and, in some cases, improved pharmacokinetic profiles compared to conventional oral dosage forms [56–58]. The efficiency of ODMTs depends on multiple interrelated factors, including disintegration rate, dissolution behavior, and the extent of buccal or pregastric absorption.

5.1 Rapid Disintegration and Dissolution

Rapid disintegration is a defining characteristic of ODMTs and is essential for ensuring quick drug release. Upon contact with saliva, the tablet matrix breaks down within seconds, facilitated by superdisintegrants such as crospovidone, croscarmellose sodium, and sodium starch glycolate [56,57]. This rapid breakup increases the surface area available for dissolution, thereby accelerating drug release.

Dissolution is a critical step following disintegration, as the drug must dissolve in saliva before absorption can occur. The rate of dissolution depends on factors such as drug solubility, particle size, and formulation composition. Hydrophilic excipients like mannitol and microcrystalline cellulose enhance wettability and promote faster dissolution [58,59].

Additionally, the formulation strategy often incorporates porous structures and low compression forces to ensure quick penetration of saliva into the tablet matrix. This leads to faster disintegration and immediate drug availability. Studies have shown that ODMTs can achieve significantly shorter disintegration times (typically less than 30 seconds), which correlates with improved dissolution profiles compared to conventional tablets [60].

1. 2. Buccal and Pregastric Absorption

One of the key advantages of ODMTs is their potential for buccal and pregastric absorption, which can bypass first-pass metabolism in the liver. When the drug is released in the oral cavity, it may be absorbed through the highly vascularized mucosal tissues of the mouth, pharynx, and esophagus [61,62].

The buccal mucosa provides a rich blood supply and relatively permeable membrane, allowing certain drugs—especially those with low molecular weight and high lipophilicity—to diffuse directly into systemic circulation. This route avoids degradation in the gastrointestinal tract and hepatic first-pass metabolism, leading to increased bioavailability [63].

Pregastric absorption also contributes to early drug uptake before the drug reaches the stomach. This is particularly beneficial for drugs that are unstable in acidic environments or extensively metabolized in the liver. However, not all drugs are suitable for buccal absorption; permeability, ionization state, and molecular size play crucial roles in determining the extent of absorption via this route [64].

1. 3. Improved Onset of Action

The combination of rapid disintegration, fast dissolution, and potential buccal absorption contributes to an improved onset of action for ODMTs. Since the drug becomes available in solution form almost immediately, it can be absorbed faster than traditional solid dosage forms that require gastric disintegration and dissolution [65].

This rapid onset is particularly advantageous in conditions requiring immediate therapeutic action, such as pain management, allergic reactions, and neurological disorders. For example, drugs like ondansetron, rizatriptan, and loratadine formulated as ODMTs demonstrate faster onset compared to their conventional counterparts [66–68].

Moreover, improved patient compliance—especially in pediatric, geriatric, and dysphagic patients ensures timely administration, which further enhances therapeutic outcomes. The convenience of administration without water also makes ODMTs suitable for emergency situations or for patients with limited access to fluids [69].

6. Regulatory Considerations

The development and approval of orodispersible mouth dissolving tablets (ODMTs) require strict adherence to regulatory frameworks to ensure their safety, efficacy, and quality. Regulatory agencies such as the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and World Health Organization (WHO) have established specific guidelines addressing pediatric formulations, orally disintegrating dosage forms, and general quality requirements. These guidelines are particularly important for ODMTs due to their unique route of administration and their frequent use in vulnerable populations such as pediatric and geriatric patients [76–78].

6.1 Guidelines for Pediatric Formulations

Pediatric drug development is a critical area of regulatory focus because children are not simply “small adults” and require age-appropriate formulations. ODMTs are especially advantageous in pediatric populations due to ease of administration without water and improved compliance [76].

Regulatory bodies such as the FDA and EMA emphasize the importance of pediatric investigation plans (PIPs) and pediatric study plans (PSPs), which ensure that medicines are appropriately evaluated for safety and efficacy in children. These frameworks require consideration of dose flexibility, palatability, and age-appropriate excipients [77].

Taste masking is particularly important in pediatric formulations, as poor palatability can lead to non-compliance. Regulatory agencies recommend the use of safe sweeteners and flavoring agents, ensuring that excipients do not pose toxicity risks to children. Additionally, excipients must be evaluated for age-specific safety, as certain substances acceptable in adults may not be suitable for infants or neonates [78].

Another key regulatory consideration is the risk of choking. ODMTs must demonstrate rapid disintegration, typically within seconds, to minimize this risk. Regulatory guidelines often require in vitro and in vivo disintegration testing to confirm suitability for pediatric use.

6.2 Regulatory Perspectives for Orally Disintegrating Dosage Forms

Regulatory agencies have established specific definitions and performance criteria for orally disintegrating tablets (ODTs), which also apply to ODMTs. According to the FDA, ODTs are solid dosage forms that disintegrate rapidly, usually within 30 seconds, when placed on the tongue [79].

The European Pharmacopoeia defines orodispersible tablets as those that disperse within 3 minutes, although most modern formulations aim for much faster disintegration [80]. These definitions guide formulation development and set benchmarks for product performance.

Regulatory evaluation of ODMTs includes assessment of:

• Disintegration time
• Dissolution profile
• Uniformity of dosage units
• Stability under varying environmental conditions

In addition, regulatory submissions must include detailed information on manufacturing processes, excipients used, and quality control measures. Technologies such as freeze-drying, direct compression, and sublimation must be validated to ensure consistent product performance [79,80].

Another important regulatory perspective is bioequivalence. ODMTs must demonstrate comparable bioavailability to conventional dosage forms unless a different pharmacokinetic profile is intended. In some cases, biowaivers may be granted based on the Biopharmaceutics Classification System (BCS), provided that the drug meets specific solubility and permeability criteria [78].

6.3 Quality and Safety Requirements

Quality and safety are central to regulatory approval of ODMTs. Regulatory authorities require compliance with Good Manufacturing Practices (GMP) to ensure consistent product quality. This includes stringent control over raw materials, manufacturing processes, and finished product testing [76].

Key quality attributes for ODMTs include:

• Mechanical strength: Tablets must be strong enough to withstand handling yet disintegrate rapidly in the mouth.
• Uniformity of content: Ensures accurate dosing, particularly critical for low-dose formulations.
• Moisture sensitivity: ODMTs are often hygroscopic, requiring specialized packaging such as blister packs to maintain stability [77].

Safety considerations extend beyond the active pharmaceutical ingredient to include excipients. Regulatory agencies require detailed toxicological evaluation of all excipients, particularly for pediatric use. Additionally, ODMTs must be free from contaminants and meet limits for impurities as specified in pharmacopeial standards [78].

Stability testing under ICH guidelines is mandatory to determine shelf life and storage conditions. These studies assess the impact of temperature, humidity, and light on product quality over time.

Finally, patient-centric factors such as palatability, mouthfeel, and ease of administration are increasingly recognized as part of quality assessment. Regulatory agencies encourage the incorporation of patient feedback into formulation development to ensure acceptability and adherence.

7. Future Perspectives

The field of orodispersible mouth dissolving tablets (ODMTs) continues to evolve rapidly, driven by advancements in material science, drug delivery technologies, and computational tools. Future developments are expected to focus on improving therapeutic efficiency, patient acceptability, and formulation precision. Key emerging areas include smart drug delivery systems, advanced taste-masking technologies, artificial intelligence (AI)-assisted formulation design, and expanded applications in pediatric and geriatric populations [81–83].

7.1 Smart Drug Delivery Systems

Smart drug delivery systems represent a transformative approach in ODMT development, integrating responsiveness and precision into conventional formulations. These systems are designed to respond to physiological triggers such as pH, temperature, or enzymatic activity, enabling controlled and targeted drug release [81].

In the context of ODMTs, smart polymers and nanocarriers can be incorporated to achieve site-specific delivery following rapid oral disintegration. For example, nanoparticles embedded within ODMTs can protect the drug during transit and release it selectively at the desired absorption site. This approach enhances bioavailability and reduces systemic side effects.

Additionally, the integration of stimuli-responsive excipients allows for modulation of drug release profiles, combining the benefits of immediate disintegration with controlled release kinetics. Such innovations are particularly promising for drugs with narrow therapeutic windows or those requiring precise dosing regimens [82].

7.2 Improved Taste Masking Technologies

Taste masking remains a critical challenge in ODMT formulation, especially for bitter drugs. Future advancements are focused on more efficient and patient-friendly taste-masking techniques that do not compromise drug release or bioavailability [83].

Emerging strategies include:

• Microencapsulation using advanced polymers, which create a barrier between the drug and taste buds
• Ion-exchange resins, which bind the drug and release it only under specific physiological conditions
• Hot-melt extrusion and spray drying, enabling uniform coating and improved stability

Nanotechnology-based approaches are also gaining attention, where drugs are encapsulated within nanoscale carriers that prevent interaction with taste receptors. These systems not only improve palatability but can also enhance solubility and dissolution rates.

Furthermore, the use of multi-sensory masking techniques, combining sweeteners, flavors, and cooling agents, is expected to improve patient experience significantly, particularly in pediatric formulations.

7.3 AI-Assisted Formulation Design

Artificial intelligence is emerging as a powerful tool in pharmaceutical development, including ODMT formulation. AI-driven models can analyze large datasets to predict optimal combinations of APIs and excipients, reducing the need for extensive trial-and-error experimentation [84].

Machine learning algorithms can be used to:

• Predict disintegration time and dissolution profiles
• Optimize excipient selection and concentration
• Identify potential stability issues early in development

AI also enables the development of digital twins virtual models of formulations that simulate performance under various conditions. This accelerates formulation development, reduces costs, and improves the likelihood of regulatory success.

Moreover, AI can assist in personalized medicine, where ODMT formulations are tailored to individual patient needs based on genetic, physiological, or demographic data. This represents a significant step toward precision therapeutics.

7.4 Expansion in Pediatric and Geriatric Therapy

ODMTs are uniquely suited for pediatric and geriatric populations, and future developments are expected to expand their use in these groups. These populations often face challenges such as difficulty swallowing (dysphagia), making conventional tablets unsuitable [85].

In pediatrics, the focus will be on:

• Age-appropriate dosing
• Enhanced taste masking
• Use of safe and non-toxic excipients

For geriatric patients, considerations include:

• Polypharmacy management
• Rapid onset of action
• Improved ease of administration

The growing emphasis on patient-centric drug design is expected to drive innovation in ODMTs, ensuring that formulations are not only effective but also convenient and acceptable to users. Regulatory agencies are also encouraging the development of such formulations, further supporting their expansion in clinical practice [81,85]

DISCUSSION

Orodispersible mouth dissolving tablets (ODMTs) have emerged as a significant advancement in oral drug delivery systems, addressing key limitations associated with conventional solid dosage forms. The overall success of ODMTs lies in their ability to combine rapid disintegration, improved patient compliance, and enhanced bioavailability, making them particularly suitable for special populations such as pediatric and geriatric patients.

One of the central themes across formulation strategies is the critical balance between mechanical strength and rapid disintegration. While superdisintegrants such as crospovidone and croscarmellose sodium enable fast tablet breakup, excessive incorporation may compromise tablet integrity. Similarly, excipients like mannitol and microcrystalline cellulose contribute to both palatability and structural stability, highlighting the importance of excipient synergy in achieving optimal performance. The discussion of formulation components underscores that ODMT development is not merely about fast disintegration but requires a multifactorial optimization approach.

Drug release and bioavailability considerations further reinforce the advantages of ODMTs. Rapid disintegration enhances dissolution rates, which can lead to a faster onset of therapeutic action. Additionally, the possibility of buccal and pregastric absorption provides a pathway to partially bypass first-pass metabolism, thereby improving systemic availability for certain drugs. However, this benefit is highly drug-dependent, as not all active pharmaceutical ingredients possess the physicochemical properties required for effective transmucosal absorption. This highlights a limitation and emphasizes the need for careful drug selection and formulation tailoring.

From a regulatory perspective, ODMTs present unique challenges and opportunities. Regulatory agencies have established clear guidelines to ensure product quality, safety, and efficacy, particularly for pediatric use. Issues such as taste masking, excipient safety, and risk of choking are given special attention. The requirement for stringent quality control measures, including disintegration testing and stability studies, reflects the complexity of these dosage forms. Moreover, harmonization between different regulatory bodies remains an ongoing challenge, especially in defining disintegration criteria and bioequivalence requirements.

Looking toward the future, technological advancements are expected to further enhance ODMT performance. The integration of smart drug delivery systems and nanotechnology offers opportunities for controlled and targeted drug release, while AI-assisted formulation design has the potential to revolutionize the development process by reducing time and cost. Improved taste-masking technologies will continue to play a crucial role in patient acceptability, particularly in pediatric formulations.

Despite these advancements, certain limitations persist. ODMTs are generally restricted to low-dose drugs, and their sensitivity to moisture necessitates specialized packaging, which can increase production costs. Additionally, scalability and manufacturing reproducibility remain challenges for certain advanced technologies such as lyophilization.

In summary, ODMTs represent a promising and patient-centric drug delivery platform with significant clinical and commercial potential. Continued research focusing on formulation optimization, regulatory harmonization, and technological innovation will be essential to fully realize their benefits and expand their applicability across a wider range of therapeutic areas.

CONCLUSION

Orodispersible mouth dissolving tablets (ODMTs) represent a significant advancement in oral drug delivery, offering multiple advantages over conventional dosage forms. Their ability to disintegrate rapidly in the oral cavity without the need for water enhances patient convenience and compliance, particularly in situations where swallowing is difficult. Additionally, ODMTs provide faster drug release and improved dissolution profiles, which can contribute to a quicker onset of therapeutic action. The incorporation of suitable excipients and taste-masking strategies further improves palatability, making these formulations more acceptable to patients.

The clinical relevance of ODMTs is especially pronounced in special populations, including pediatric, geriatric, and dysphagic patients. In children, ODMTs address challenges related to swallowing and taste sensitivity, while in elderly patients, they improve medication adherence and reduce the risk of choking. Furthermore, in patients with neurological disorders or those who are bedridden, ODMTs offer a practical and effective alternative to traditional tablets and capsules. Their ease of administration also makes them valuable in emergency and outpatient settings.

Looking ahead, ODMTs hold considerable promise as part of next-generation oral drug delivery systems. Advances in formulation technologies, such as nanocarriers, smart polymers, and AI-assisted design, are expected to further enhance their performance and expand their therapeutic applications. With continued innovation and regulatory support, ODMTs are poised to play an increasingly important role in patient-centric drug delivery, bridging the gap between convenience, efficacy, and advanced pharmaceutical design.

REFERENCES

1. Aulton ME, Taylor KMG. Aulton’s Pharmaceutics: The Design and Manufacture of Medicines. 5th ed. Elsevier; 2018.
2. Stegemann S, Gosch M, Breitkreutz J. Swallowing dysfunction and dysphagia in the elderly. Int J Pharm. 2012;430(1–2):1–11.
3. Mennella JA, Spector AC, Reed DR, Coldwell SE. The bad taste of medicines: overview of basic research on bitter taste. Clin Ther. 2013;35(8):1225–1246.
4. Fu Y, Yang S, Jeong SH, Kimura S, Park K. Orally fast disintegrating tablets: developments, technologies, and clinical applications. Crit Rev Ther Drug Carrier Syst. 2004;21(6):433–476.
5. Shah RB, Tawakkul MA, Khan MA. Comparative evaluation of taste masking technologies. Expert Opin Drug Deliv. 2008;5(6):601–612.
6. Habib W, Khankari R, Hontz J. Fast-dissolve drug delivery systems. Crit Rev Ther Drug Carrier Syst. 2000;17(1):61–72.
7. Stoltenberg I, Breitkreutz J. Orally disintegrating mini-tablets: a novel dosage form for pediatric use. Eur J Pharm Biopharm. 2011;78(3):462–469.
8. Spomer N, Klingmann V, Stoltenberg I, Lerch C, Meissner T, Breitkreutz J. Acceptance of uncoated mini-tablets in young children. J Pediatr. 2012;160(1):148–152.
9. Klingmann V, Seitz A, Meissner T, Breitkreutz J, Moeltner A, Bosse HM. Acceptability of multiple uncoated mini-tablets in infants and toddlers. Eur J Pharm Biopharm. 2015;93:278–284.
10. Preis M, Pein M, Breitkreutz J. Development of a taste-masked orodispersible film containing dimenhydrinate. Pharmaceutics. 2012;4(4):551–562.
11. Breitkreutz J, Boos J. Paediatric and geriatric drug delivery. Expert Opin Drug Deliv. 2007;4(1):37–45.
12. Standing JF, Tuleu C. Paediatric formulations—getting to the heart of the problem. Int J Pharm. 2005;300(1–2):56–66.
13. Mennella JA, Beauchamp GK. Optimizing oral medications for children. Clin Ther. 2008;30(11):2120–2132.
14. Nunn AJ, Williams J. Formulation of medicines for children. Br J Clin Pharmacol. 2005;59(6):674–676.
15. European Medicines Agency. Reflection paper on the pharmaceutical development of medicines for paediatric use. EMA; 2013.
16. Stegemann S, Gosch M, Breitkreutz J. Swallowing dysfunction and dysphagia in the elderly. Int J Pharm. 2012;430(1–2):1–11.
17. Maher RL, Hanlon J, Hajjar ER. Clinical consequences of polypharmacy in elderly. Expert Opin Drug Saf. 2014;13(1):57–65.
18. Elliott RA. Problems with medication use in the elderly: an Australian perspective. J Pharm Pract Res. 2006;36(1):58–66.
19. Turner MD, Ship JA. Dry mouth and its effects on the oral health of elderly people. J Am Dent Assoc. 2007;138(Suppl):15S–20S.
20. van Riet-Nales DA, Schobben AFAM, Vromans H, Egberts TCG, Rademaker CMA. Safe and effective pharmacotherapy in infants and preschool children. Br J Clin Pharmacol. 2016;82(3):563–576.
21. Tuleu C, Breitkreutz J. Educational paper: formulation-related issues in pediatric clinical pharmacology. Eur J Pediatr. 2013;172(6):717–720.
22. Mennella JA, Beauchamp GK. Optimizing oral medications for children and older adults. Clin Ther. 2008;30(11):2120–2132.
23. European Medicines Agency. Guideline on pharmaceutical development of medicines for paediatric use. EMA; 2013.
24. World Health Organization. WHO model list of essential medicines for children. WHO; 2019.
25. Dening KH, Greenish W, Jones L, Mandal U, Sampson EL. Barriers to providing oral medications to older adults with dysphagia. Age Ageing. 2015;44(1):41–46.
26. Stoltenberg I, Breitkreutz J. Orally disintegrating mini-tablets: a novel dosage form for paediatric use. Eur J Pharm Biopharm. 2011;78(3):462–469.
27. Fu Y, Yang S, Jeong SH, Kimura S, Park K. Orally fast disintegrating tablets: developments and technologies. Crit Rev Ther Drug Carrier Syst. 2004;21(6):433–476.
28. Spomer N, Klingmann V, Stoltenberg I, Lerch C, Meissner T, Breitkreutz J. Acceptance of mini-tablets in young children. J Pediatr. 2012;160(1):148–152.
29. Klingmann V, Seitz A, Meissner T, Breitkreutz J. Acceptability of multiple mini-tablets in infants and toddlers. Eur J Pharm Biopharm. 2015;93:278–284.
30. Preis M, Breitkreutz J. Orally disintegrating dosage forms: innovations and applications. Expert Opin Drug Deliv. 2017;14(9):1051–1061.
31. Aulton ME, Taylor KMG. Aulton’s Pharmaceutics: The Design and Manufacture of Medicines. 5th ed. Elsevier; 2018.
32. Ghebre-Sellassie I. Multiparticulate oral drug delivery systems. New York: Marcel Dekker; 1994.
33. Kleinebudde P. Roll compaction/dry granulation: pharmaceutical applications. Eur J Pharm Biopharm. 2004;58(2):317–326.
34. United States Pharmacopeia. Uniformity of dosage units USP <905>. Rockville: USP Convention; 2020.
35. Shah RB, Tawakkul MA, Khan MA. Taste masking technologies in oral pharmaceuticals. Expert Opin Drug Deliv. 2008;5(6):601–612.
36. Fu Y, Yang S, Jeong SH, Kimura S, Park K. Orally fast disintegrating tablets: developments, technologies, taste-masking and clinical studies. Crit Rev Ther Drug Carrier Syst. 2004;21(6):433–476.
37. Chang RK, Guo X, Burnside BA, Couch RA. Fast-dissolving tablets. Pharm Technol. 2000;24(6):52–58.
38. Seager H. Drug-delivery products and the Zydis fast-dissolving dosage form. J Pharm Pharmacol. 1998;50(4):375–382.
39. Dobetti L. Fast-melting tablets: developments and technologies. Pharm Technol Eur. 2001;13(9):44–50.
40. Kuchekar BS, Badhan AC, Mahajan HS. Mouth dissolving tablets: a novel drug delivery system. Pharma Times. 2003;35(1):7–9.
41. Sohi H, Sultana Y, Khar RK. Taste masking technologies in oral pharmaceuticals: recent developments and approaches. Drug Dev Ind Pharm. 2004;30(5):429–448.
42. Mennella JA, Beauchamp GK. Optimizing oral medications for children. Clin Ther. 2008;30(11):2120–2132.
43. Ghosh TK, Ghosh A, Prasad D. A review on new generation orodispersible tablets and its future prospective. Int J Pharm Pharm Sci. 2011;3(1):1–7.
44. Desai PM, Liew CV, Heng PW. Review of disintegrants and the disintegration phenomena. J Pharm Sci. 2016;105(9):2545–2555.
45. Zhao N, Augsburger LL. The influence of swelling capacity of superdisintegrants in different pH media on the dissolution of hydrochlorothiazide from directly compressed tablets. AAPS PharmSciTech. 2005;6(1):E120–E126.
46. Shihora H, Panda S. Superdisintegrants, utility in dosage form: a quick review. J Pharm Sci Biosci Res. 2011;1(3):148–153.
47. Rowe RC, Sheskey PJ, Quinn ME. Handbook of Pharmaceutical Excipients. 6th ed. London: Pharmaceutical Press; 2009.
48. Bolhuis GK, Chowhan ZT. Materials for direct compaction. In: Alderborn G, Nyström C, editors. Pharmaceutical Powder Compaction Technology. New York: Marcel Dekker; 1996. p. 419–500.
49. Thoorens G, Krier F, Leclercq B, Carlin B, Evrard B. Microcrystalline cellulose, a direct compression binder in a quality by design environment—a review. Int J Pharm. 2014;473(1–2):64–72.
50. Bühler V. Polyvinylpyrrolidone Excipients for Pharmaceuticals. Berlin: Springer; 2005.
51. Shirwaikar AA, Prabu SL, Kumar GA. Herbal excipients in novel drug delivery systems. Indian J Pharm Sci. 2008;70(4):415–422.
52. Bolhuis GK, Lerk CF. Film coating of tablets with magnesium stearate. Int J Pharm. 1981;8(2–3):137–146.
53. Aulton ME, Taylor K. Aulton’s Pharmaceutics: The Design and Manufacture of Medicines. 4th ed. London: Churchill Livingstone; 2013.
54. Shah RB, Tawakkul MA, Khan MA. Comparative evaluation of flow for pharmaceutical powders and granules. AAPS PharmSciTech. 2008;9(1):250–258.
55.   Douroumis D. Orally disintegrating dosage forms and taste-masking technologies; 2010. Expert Opin Drug Deliv. 2010;7(5):665–675.
56. Fu Y, Yang S, Jeong SH, Kimura S, Park K. Orally fast disintegrating tablets: developments, technologies, taste-masking and clinical studies. Crit Rev Ther Drug Carrier Syst. 2004;21(6):433–476.
57. Desai PM, Liew CV, Heng PW. Review of disintegrants and the disintegration phenomena. J Pharm Sci. 2016;105(9):2545–2555.
58. Ghosh TK, Ghosh A, Prasad D. A review on new generation orodispersible tablets and its future prospective. Int J Pharm Pharm Sci. 2011;3(1):1–7.
59. Thoorens G, Krier F, Leclercq B, Carlin B, Evrard B. Microcrystalline cellulose, a direct compression binder in a quality by design environment—a review. Int J Pharm. 2014;473(1–2):64–72.
60. Chang RK, Guo X, Burnside BA, Couch RA. Fast-dissolving tablets. Pharm Technol. 2000;24(6):52–58.
61. Shojaei AH. Buccal mucosa as a route for systemic drug delivery: a review. J Pharm Pharm Sci. 1998;1(1):15–30.
62. Patel VF, Liu F, Brown MB. Advances in oral transmucosal drug delivery. J Control Release. 2011;153(2):106–116.
63. Senel S, Hincal AA. Drug permeation enhancement via buccal route: possibilities and limitations. J Control Release. 2001;72(1–3):133–144.
64.   Rathbone MJ, Drummond BK, Tucker IG. Oral mucosal drug delivery. New York: Marcel Dekker; 1996.
65. Seager H. Drug-delivery products and the Zydis fast-dissolving dosage form. J Pharm Pharmacol. 1998;50(4):375–382.
66. Sweetman SC. Martindale: The Complete Drug Reference. 36th ed. London: Pharmaceutical Press; 2009.
67. Biradar SS, Bhagavati ST, Kuppasad IJ. Fast dissolving drug delivery systems: a brief overview. Internet J Pharmacol. 2006;4(2):1–7.
68. Sastry SV, Nyshadham JR, Fix JA. Recent technological advances in oral drug delivery: a review. Pharm Sci Technolo Today. 2000;3(4):138–145.
69.   Allen LV, Wang B. Process for making a rapidly dissolving dosage form. US Patent. 2003;6:589–554.
70. Dixit RP, Puthli SP. Oral strip technology: overview and future potential. J Control Release. 2009;139(2):94–107.
71. Boateng JS, Ayensu I, Okeke CI. Oral fast dissolving films: innovations in formulation and technology. Recent Pat Drug Deliv Formul. 2015;9(1):34–48.
72. Preis M, Knop K, Breitkreutz J. Mechanical strength test for orodispersible and buccal films. Int J Pharm. 2014;461(1–2):22–29.
73. European Pharmacopoeia Commission. Orodispersible tablets monograph. Eur Pharm. 2014.
74. US Food and Drug Administration. Guidance for industry: orally disintegrating tablets. Silver Spring: FDA; 2008.
75. Habib W, Khankari R, Hontz J. Fast-dissolve drug delivery systems. Crit Rev Ther Drug Carrier Syst. 2000;17(1):61–72.
76. US Food and Drug Administration. Guidance for industry: orally disintegrating tablets. Silver Spring (MD): FDA; 2008.
77. European Medicines Agency. Guideline on pharmaceutical development of medicines for paediatric use. London: EMA; 2013.
78. World Health Organization. Development of paediatric medicines: points to consider in pharmaceutical development. Geneva: WHO; 2012.
79. US Food and Drug Administration. Orally disintegrating tablets: regulatory considerations. Silver Spring (MD): FDA; 2008.
80. European Pharmacopoeia Commission. Orodispersible tablets monograph. Strasbourg: Council of Europe; 2014.
81. anger R. Drug delivery and targeting. Nature. 1998;392(6679 Suppl):5–10.
82. Torchilin VP. Multifunctional nanocarriers. Adv Drug Deliv Rev. 2012;64 Suppl:302–315.
83. Douroumis D. Orally disintegrating dosage forms and taste-masking technologies. Expert Opin Drug Deliv. 2010;7(5):665–675.
84. Paul D, Sanap G, Shenoy S, Kalyane D, Kalia K, Tekade RK. Artificial intelligence in drug discovery and development. Drug Discov Today. 2021;26(1):80–93.
85. Mennella JA, Beauchamp GK. Optimizing oral medications for children. Clin Ther. 2008;30(11):2120–2132.